Premium
Time course of serum testosterone and luteinizing hormone levels after cessation of long‐term luteinizing hormone‐releasing hormone agonist treatment in patients with prostate cancer
Author(s) -
Kaku Haruki,
Saika Takashi,
Tsushima Tomoyasu,
Ebara Shin,
Senoh Takashi,
Yamato Toyoko,
Nasu Yasutomo,
Kumon Hiromi
Publication year - 2005
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20341
Subject(s) - medicine , luteinizing hormone , agonist , prostate cancer , testosterone (patch) , endocrinology , hormone , androgen deprivation therapy , leuprorelin , hormone therapy , cancer , gonadotropin releasing hormone , receptor , breast cancer
In order to elucidate the influence of hormone‐releasing hormone (LH‐RH) agonist therapy cessation on pituitary/testicular function and its clinical implications, we investigated prospectively hormonal (luteinizing hormone: LH; testosterone: T) responses in patients with prostate cancer who received long‐term LH‐RH 10 agonist therapy. Patients and Methods A consecutive 32 patients who had received LH‐RH agonist therapy over 24 months were enrolled. As a baseline, T and LH were measured at the time of LH‐RH agonist therapy cessation, monthly for 3 months, and subsequently, every 3 months. Results The median duration of LH‐RH agonist therapy was 30 months (24–87 months) with median follow‐up duration of 24 months following cessation. All patients had castrated T levels and suppressed LH levels at baseline. Median duration of castrated T levels following cessation was 6 months. Median time to normalization of T levels was 24 months. LH levels returned to normal within 3 months in all cases. Patients who received androgen deprivation therapy for 30 months or longer required a longer time for recovery of T levels. Patients over 65 years of age showed a statistically significant longer time for recovery of T levels ( P = 0.0167). Conclusions Long‐term LH‐RH agonist therapy has remarkable effects on serum T level that last for a significant time after cessation, a fact that should be applied to the interpretation of both PSA and serum T levels after cessation of androgen deprivation therapy. © 2005 Wiley‐Liss, Inc.